Ignite Creation Date:
2024-05-05 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00148798
Status:
COMPLETED
Last Update Posted:
2014-06-25
First Post:
2005-09-07
Brief Title:
Study of CisplatinVinorelbine - Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer FLEX
Sponsor:
Merck KGaA Darmstadt Germany
Organization:
Merck KGaA Darmstadt Germany
Study Overview
Official Title:
Open Randomized Controlled Multicenter Phase III Study Comparing CisplatinVinorelbine Plus Cetuximab Versus CisplatinVinorelbine as First-line Treatment for Patients With Epidermal Growth Factor Receptor Expressing EGFR-expressing Advanced NSCLC
Status:
COMPLETED
Status Verified Date:
2014-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
FLEX
Brief Summary:
The purpose of this trial is to investigate the efficacy of cetuximab in combination with chemotherapy in comparison to chemotherapy alone in patients with advanced non small cell lung cancer who did not received prior chemotherapy Overall survival will be taken as primary measure of efficacy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None